← Eichor
Study identifier: NCT06362577 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Clinical Study of HIFU for Localized Prostate Cancer

Condition: Localized Prostate Cancer  ·  Sponsor: RenJi Hospital

PhaseN/A
Planned participants60
Who can joinMale, 40 Years to no upper limit
Healthy volunteersNo

About this study

In this study, the safety and effectiveness data of Sonablate system, a transrectal high-intensity focused ultrasound therapeutic instrument, in the treatment of localized prostate cancer were collected, and the treatment conditions of patients with other methods (such as radical prostatectomy) were compared and analyzed. Observe the differences in treatment effect, survival rate, postoperative PSA, recurrence and complications. To analyze and compare the clinical outcome, postoperative complications and tumor control of HIFU and robot-assisted laparoscopic radical prostatectomy for localized prostate cancer, and to explore the effectiveness and safety of HIFU in the treatment of localized prostate cancer, so as to provide an alternative treatment for localized prostate cancer.

This description comes directly from the study's public registry record.

Talk to the study team

Wang YanQing, Master's  ·  13917826792  ·  iwangyq@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

Renji Hospital-Shanghai Jiao Tong University School of MedicineShanghai, Shanghai Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06362577